Fennec Pharmaceuticals (TSE:FRX) Insider Southpoint Capital Advisors Lp Sells 20,609 Shares

Posted by Teresa Graham on Oct 11th, 2025

Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report) insider Southpoint Capital Advisors Lp sold 20,609 shares of the company’s stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of C$12.89, for a total transaction of C$265,650.01. Following the transaction, the insider owned 4,010,100 shares in the company, valued at C$51,690,189. The trade was a 0.51% decrease in their ownership of the stock.

Southpoint Capital Advisors Lp also recently made the following trade(s):

On Tuesday, October 7th, Southpoint Capital Advisors Lp sold 26,900 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$13.23, for a total transaction of C$355,887.00.
On Wednesday, October 8th, Southpoint Capital Advisors Lp sold 19,605 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$13.07, for a total transaction of C$256,237.35.

Fennec Pharmaceuticals Trading Down 7.4%

Shares of FRX opened at C$12.30 on Friday. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The firm’s 50-day moving average is C$12.20 and its two-hundred day moving average is C$10.73. Fennec Pharmaceuticals Inc. has a twelve month low of C$5.65 and a twelve month high of C$13.83. The firm has a market capitalization of C$342.33 million, a P/E ratio of -27.33 and a beta of 2.48.

About Fennec Pharmaceuticals

(Get Free Report)

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.